State Street SPDR S&P Pharmaceuticals ETF
$66.31−2.48 (−3.60%)
- Expense ratio
- 0.35%
- Fund size
- $558M
- 1Y return
- +48.0%
- Yield · Last 12 months
- 0.40%
- Holdings
- 63
- Volume · 30D
- 0.1M sh
- NAV per share
- $67.59
- 52W range
The ETF.net XPH Grade
Score 66 of 100 sits in the B band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.AScore 79Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.BScore 58Category rankRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.CScore 44Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.BScore 61Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.AScore 90Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.AScore 71Category rank
Our read on XPH
BMost pharma funds are a mega-cap sandwich. XPH equal-weights instead, so a small-cap drugmaker gets roughly the same say as an industry giant, across about 60 names, for 0.35% a year.
The fund seeks to provide exposure to the pharmaceuticals segment of the S&P TMI.
Why people hold it
- Modified equal weighting with quarterly rebalances: the index trims what has run and keeps real room for small and mid-cap drugmakers, not just the household names.ssga.com
- At 0.35%, the cheapest sticker in its pharma peer group and well under the group median of 0.57% (PPH 0.36%, IHE 0.37%, PJP 0.57%, FTXH 0.60%).
- Pure pharma, not a health care grab bag: it draws only from the pharmaceuticals segment of the S&P Total Market Index. No insurers, hospitals or device makers.ssga.com
- Running since 2006 under a single index rulebook, with assets in the mid-size range and about 60 holdings behind it.
Worth knowing
- Equal weighting pulls the portfolio down the cap ladder, where trial results and FDA decisions can swing a single stock hard. Expect a bumpier ride than mega-cap pharma.ssga.com
- One industry, one country. Drug pricing rules and patent cliffs hit the whole basket at once.
- Moderately traded rather than a volume monster, so spreads can widen. Limit orders are the usual answer.
XPH Holdings
- Stocks
- 63
- 20%
- AMRX
Sectors
- Health Care100.0%
Geography
- United States96.28%
- Ireland3.72%
XPH Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
XPH$14,801
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | XPH |
|---|---|
| Year to date | +23.1% |
| 1 month | −5.5% |
| 3 months | +10.8% |
| 1 year | +48.0% |
| 3 years | +20.6% |
| 5 years | +9.2% |
| 10 years | +5.0% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | XPH |
|---|---|---|
| 2026 YTD | +23.1% | |
| 2025 | +31.6% | |
| 2024 | +4.9% | |
| 2023 | +3.0% | |
| 2022 | −9.8% | |
| 2021 | −10.5% | |
| 2020 | +14.7% |
XPH in the news
XPH Dividends
- 0.40%
- $0.27
- $0.04 per share
- Quarterly
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Sep 21, 2026 | Pays Sep 23, 2026 | $0.04 |
| Jun 22, 2026 | Jun 24, 2026 | $0.06 |
| Mar 23, 2026 | Mar 25, 2026 | $0.06 |
| Dec 22, 2025 | Dec 24, 2025 | $0.11 |
| Sep 22, 2025 | Sep 24, 2025 | $0.10 |
| Jun 23, 2025 | Jun 25, 2025 | $0.10 |
| Mar 24, 2025 | Mar 26, 2025 | $0.15 |
| Dec 23, 2024 | Dec 26, 2024 | $0.15 |
| Sep 23, 2024 | Sep 25, 2024 | $0.19 |
| Jun 24, 2024 | Jun 26, 2024 | $0.16 |
| Mar 18, 2024 | Mar 21, 2024 | $0.17 |
| Dec 18, 2023 | Dec 21, 2023 | $0.17 |
XPH Risk
- 20.6%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.72
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −30.9%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.72
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
XPH Cost
0.35%
XPH0.35%
- The middle half of Pharma & Therapeutics funds
- Median 0.58%
1 of the 9 Pharma & Therapeutics funds charge less.